Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4

3(37.5%)

Phase 1

3(37.5%)

Phase 3

1(12.5%)

N/A

1(12.5%)

8Total

Phase 4(3)

Phase 1(3)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07439848Phase 1Recruiting

Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis

Role: collaborator

NCT06866158Phase 1Active Not Recruiting

Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease

Role: collaborator

NCT06525155Phase 3Recruiting

Effect GnRH Agonist Administration in Endometriosis Cyst Patients

Role: lead

NCT05939817Phase 4Completed

The Effect of Intralesian Injection of Umbilical Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide on Type 1:3 Collagen Ratio and Interleukin-10 Levels in Keloid: A Randomised Controlled Trial

Role: lead

NCT05887804Phase 4Completed

Comparison of Keloid Volume and Symptoms Reduction Between Intralesional Umbilical-Cord Mesenchymal Stem Cells, Its Conditioned Medium, and Triamcinolone Acetonide Injection as Keloid Therapy: A Randomised Controlled Trial

Role: lead

NCT04728906Not ApplicableUnknown

Heart Patch for Myocardial Infarction COVID-19

Role: lead

NCT04407208Phase 1Completed

Convalescent Plasma Therapy in Patients With COVID-19

Role: collaborator

NCT03626298Phase 4Completed

Efficacy and Tolerability of Nicotinamide Plus Cream for Moderate Acne Vulgaris in Indonesia

Role: lead

All 8 trials loaded